Jabil Circuit has announced the completion of its $665 million acquisition of contract plastics manufacturer Nypro, which makes dry powder inhalers and nasal spray pumps for pharmaceutical companies among other products. According to Jabil, it will keep the Nypro name and will absorb approximately 10,000 Nypro employees. Nypro will keep its headquarters in Clinton, … [Read more...] about Jabil completes acquisition of Nypro
News
Study shows feasibility of nasal dosing of diazepam during seizure
Acorda Therapeutics announced results from a clinical study of the pharmacokinetics, safety, and tolerability of its diazepam nasal spray for the treatment of cluster seizures in epilepsy patients at the recent International Congress of the International League Against Epilepsy (ILAE) and International Bureau for Epilepsy (IBE). Over the course of the study, 31 … [Read more...] about Study shows feasibility of nasal dosing of diazepam during seizure
Arikace meets primary endpoint in Phase 3 study
According to Insmed, a Phase 3 study of more than 300 cystic fibrosis patients has demonstrated the non-inferiority of once-daily Arikace inhaled liposomal amikacin to twice-daily TOBI tobramycin inhalation solution, meeting the study's primary endpoint. The company also announced that the FDA has granted Arikace Fast Track and Qualified Infectious Disease Product … [Read more...] about Arikace meets primary endpoint in Phase 3 study
Zogenix to co-promote Migranal nasal spray in US
Zogenix has announced that it has reached an agreement with Valeant to begin selling Migranal dihydroergotamine mesylate nasal spray in the US beginning in late July 2013 and extending initially through the end of 2015. Valeant will pay Zogenix a quarterly service fee based on a percentage of sales exceeding a specified baseline. Zogenix CEO Roger L. Hawley … [Read more...] about Zogenix to co-promote Migranal nasal spray in US
RespiTech gets grant for inhaled pulmonary fibrosis treatment
The Australia Research Council (ARC) has awarded a $370,000 Linkage grant to Paul Young, Daniela Traini, and Brian Oliver of RespiTech and the cell biology group at the Woolcock Institute of Medical Research (WIMR) for development of an aerosol anti-fibrotic for the treatment of pulmonary lung fibrosis. The team's research proposal was titled "A tight squeeze: … [Read more...] about RespiTech gets grant for inhaled pulmonary fibrosis treatment
Alexza hires Michael Holfinger as VP, Manufacturing & Global Supply Chain Management
Alexza Pharmaceuticals has announced the appointment of Michael S. Holfinger as Vice President, Manufacturing & Global Supply Chain Management. Holfinger was most recently Vice President, Manufacturing & CMC Development at Affymax. Alexza recently announced that Teva will market the company's Adasuve inhaled loxapine in the US. Holfinger commented, "With the … [Read more...] about Alexza hires Michael Holfinger as VP, Manufacturing & Global Supply Chain Management
Kamada gets new patents for inhaled AAT
Israeli phamaceutical company Kamada Ltd announced that it has received Russian and Australian patents related to its inhaled alpha-1 antitrypsin (AAT) for the treatment of lung diseases. Russian Patent No. 2472524 is titled “Alpha-1 Antitrypsin for treating exacerbation episodes of pulmonary diseases,” and the Australian Patent, No. 2007213344, is titled “Pulmonary … [Read more...] about Kamada gets new patents for inhaled AAT
Coster announces US DMF number for MDI valves
Italian aerosol device and filling machine company Coster Pharma has announced that its Type 3 Drug Master File (DMF) for two of its MDI valves to the FDA has been issued the DMF number 26960. Both of the 20mm valves are manufactured at the company's clean room facility in Trento, Italy. The 20DR valve is available for 50, 65, 75, and 100 µl dosing, and the 20DPH … [Read more...] about Coster announces US DMF number for MDI valves
Civitas gets second grant for inhaled L-dopa from Michael J. Fox Foundation
Civitas Therapeutics has received a $1 million grant from The Michael J. Fox Foundation for Parkinson’s Research for development of CVT-301 inhaled L-dopa for the treatment of motor fluctuations in Parkinson's disease patients, the company said. The grant will support a Phase 2b trial of the carrier-free dry powder formulation. The foundation previously awarded … [Read more...] about Civitas gets second grant for inhaled L-dopa from Michael J. Fox Foundation
MicroDose Therapeutx acquired by Teva
Teva has announced that it will acquire inhaled drug developer MicroDose Therapeutx for $40 million up front plus up to $125 million in development and regulatory milestone payments, as well as sales milestone payments and royalties. Calling the acquisition "a significant step toward expanding its respiratory pipeline," the company cited MicroDose’s proprietary dry … [Read more...] about MicroDose Therapeutx acquired by Teva